Loading clinical trials...
Loading clinical trials...
A Phase I/ II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab in Combination With Brentuximab Vedotin in Subjects With Relapsed Refractory Non Hodgkin Lymphomas With CD30 Expression (CheckMate 436: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 436)
The purpose of this study is to determine whether Nivolumab, in combination with brentuximab vedotin, is safe and effective in patients with certain subtypes of non-Hodgkin's lymphomas with CD30 expression that have not responded to treatment or have come back. The subtypes we are studying are Diffuse Large B-Cell Lymphoma (DLBCL), Peripheral T-Cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL), Primary Mediastinal Large B-Cell Lymphoma (PMBL) and Mediastinal Gray Zone Lymphoma (MGZL).
Age
15 - No limit years
Sex
ALL
Healthy Volunteers
No
Local Institution - 0017
Birmingham, Alabama, United States
University Of Miami Sylvester Comprehensive Cancer Center
Miami, Florida, United States
Local Institution - 0012
Tampa, Florida, United States
Winship Cancer Institute.
Atlanta, Georgia, United States
University Of Chicago
Chicago, Illinois, United States
Mayo Clinic
Rochester, Minnesota, United States
Washington University School Of Medicine
St Louis, Missouri, United States
Local Institution - 0003
New York, New York, United States
Local Institution - 0010
New York, New York, United States
University Of Rochester
Rochester, New York, United States
Start Date
February 11, 2016
Primary Completion Date
January 16, 2020
Completion Date
February 7, 2022
Last Updated
March 7, 2023
145
ACTUAL participants
Nivolumab
BIOLOGICAL
Brentuximab Vedotin
DRUG
Lead Sponsor
Bristol-Myers Squibb
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions